Ionis Pharmaceuticals, Inc.

Equities

IONS

US4622221004

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2024-07-16 EDT			5-day change	1st Jan Change
49.84 ^USD	+4.77%		+5.95%	-1.48%

06-27	Stifel Adjusts Ionis Pharmaceuticals Price Target to $53 From $50, Maintains Hold Rating	MT
06-25	Ionis Pharmaceuticals' Shares Rise After FDA Accepts Metabolic Disorder Drug Candidate for Priority Review	MT

Ionis Pharmaceuticals, Inc. announced that it expects to receive $100.01 million in funding from Novartis AG

January 05, 2017

Ionis Pharmaceuticals, Inc. (NasdaqGS:IONS) announced entered into collaboration agreement with new investor Novartis AG (SWX:NOVN) for private placement of 1,631,435 shares at a price of $61.30 per share for gross proceeds of $100,006,965.5 on January 6, 2017.

Latest news about Ionis Pharmaceuticals, Inc.

Stifel Adjusts Ionis Pharmaceuticals Price Target to $53 From $50, Maintains Hold Rating	06-27	MT
Ionis Pharmaceuticals' Shares Rise After FDA Accepts Metabolic Disorder Drug Candidate for Priority Review	06-25	MT
Ionis Pharmaceuticals Says FDA Accepts Metabolic Disorder Drug Candidate for Priority Review	06-25	MT
Ionis Pharmaceuticals, Inc. Announces olezarsen FCS New Drug Application Accepted for Priority Review and Enrollment in Phase 3 sHTG Program Completed	06-25	CI
ANALYST RECOMMENDATIONS : Home Depot, Apple, Micron Technology, Anglo American, United Utilities...	06-21
Ionis Pharmaceuticals Insider Sold Shares Worth $644,640, According to a Recent SEC Filing	06-20	MT
Transcript : Ionis Pharmaceuticals, Inc. Presents at TD Cowen?s Genetic Medicines & RNA Summit, Jun-20-2024 03:30 PM	06-20
Ionis Pharmaceuticals Says Otsuka Obtains Rights for Investigational Hereditary Angioedema Treatment in Asia Pacific	06-18	MT
Ionis Pharmaceuticals, Inc. Announces Expand Licensing Agreement with Otsuka Pharmaceutical Co., Ltd	06-18	CI
Investors need more time to assess Fed comments	06-14
Bernstein Upgrades Ionis Pharmaceuticals to Market Perform From Underperform, Adjusts Price Target to $44 From $37	06-14	MT
ANALYST RECOMMENDATIONS : Adobe, Bank of America, Boeing, Nvidia, Wise...	06-14
Transcript : Ionis Pharmaceuticals, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-10-2024 through Jun-13-2024	06-11
Transcript : Ionis Pharmaceuticals, Inc. - Special Call	06-06
Ionis Reports 'Positive Results' From Studies of Investigational Treatment for Hereditary Angioedema	05-31	MT
Transcript : Ionis Pharmaceuticals, Inc. - Special Call	05-31
Ionis Pharmaceuticals, Inc. Presents Positive Results from OASIS-HAE and OASISplus Studies of Investigational Medicine Donidalorsen in Patients with Hereditary Angioedema	05-31	CI
Sector Update: Health Care Stocks Mixed in Late Afternoon Trading	05-16	MT
Sector Update: Health Care Stocks Ease Thursday Afternoon	05-16	MT
US Equity Indexes Trade Mixed as Investors Weigh Macro Data; Dow Touches Record High	05-16	MT
Sector Update: Health Care	05-16	MT
Dow Touches 40,000 Mark for First Time as Macroeconomic Data Signals Economic Weakness	05-16	MT
Ionis Pharmaceuticals Says Potential Angelman Syndrome Therapy Improves Symptoms in Phase 1/2a Study	05-16	MT
Stocks in motion: Walmart, Chubb, Deere...	05-16
Sector Update: Health Care Stocks Steady Premarket Thursday	05-16	MT

Chart Ionis Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Ionis Pharmaceuticals, Inc. is engaged in ribonucleic acid (RNA)-targeted therapeutics. The Company has five marketed medicines and a pipeline in neurology, cardiology, and other areas of high patient need. It has nine medicines in Phase III development and multiple additional medicines in early and mid-stage development. The Companyâs products include SPINRAZA, QALSODY, WAINUA, TEGSEDI and WAYLIVRA. SPINRAZA is used for the treatment of patients with spinal muscular atrophy (SMA), a progressive, debilitating and often fatal genetic disease. QALSODY is an antisense medicine that is used for the treatment of adult patients with superoxide dismutase 1 amyotrophic lateral sclerosis (SOD1-ALS), a rare, neurodegenerative disorder that causes progressive loss of motor neurons leading to death. WAINUA is a self-administered subcutaneous LIgand-Conjugated Antisense (LICA) medicine used for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis (ATTRv-PN).

Sector

Biotechnology & Medical Research

Calendar

2024-07-22 - ION582 Phase 1/2a HALOS Study Results Call

More about the company

Income Statement Evolution

More financial data

Ratings for Ionis Pharmaceuticals, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

49.84 USD

Average target price

59.39 USD

Spread / Average Target

+19.16%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
IONIS PHARMACEUTICALS, INC.	-1.48%	7.27B
MODERNA, INC.	+25.83%	47.96B
IQVIA HOLDINGS INC.	+0.69%	42.45B
LONZA GROUP AG	+44.08%	41.47B
ALNYLAM PHARMACEUTICALS, INC.	+30.52%	31.6B
ICON PUBLIC LIMITED COMPANY	+22.30%	28.63B
CELLTRION, INC.	-6.35%	28.03B
UNITED THERAPEUTICS CORPORATION	+49.25%	14.56B
MEDPACE HOLDINGS, INC.	+49.18%	14.14B
BIO-TECHNE CORPORATION	+3.45%	12.58B

Other Biotechnology & Medical Research